Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy

Histone acetylation is a diagnostic feature of transcriptionally active chromatin. The group of enzymes, histone acetyltransferases (HATs), involved in this crucial step of gene regulation, covalently modifies the N-terminal lysine residues of histones by the addition of an acetyl group from acetyl...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical pharmacology 2004-09, Vol.68 (6), p.1215-1220
Main Authors: Varier, Radhika A, Swaminathan, V, Balasubramanyam, Karanam, Kundu, Tapas K
Format: Article
Language:English
Subjects:
Acetylation
Acetyltransferases - antagonists & inhibitors
Acetyltransferases - genetics
Acetyltransferases - metabolism
Anacardic acid
Animals
Biological and medical sciences
Chromatin - metabolism
Chromatin modification
CTPB
Enzyme Inhibitors - pharmacology
Forecasting
Garcinol
Histone acetyltransferase (HAT)
Histone Acetyltransferases
Histones - metabolism
Humans
Medical sciences
p300
PCAF
Pharmacology. Drug treatments
Transcription
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Histone acetylation is a diagnostic feature of transcriptionally active chromatin. The group of enzymes, histone acetyltransferases (HATs), involved in this crucial step of gene regulation, covalently modifies the N-terminal lysine residues of histones by the addition of an acetyl group from acetyl coenzyme A. Dysfunction of these enzymes is often associated with several diseases, ranging from neurodegenerative disorders to cancer. These enzymes thus are potential new targets for therapeutics. We have discovered few small molecule compounds, which target HATs and either activate or inhibit the enzyme potently. These compounds would be useful as biological switching molecules for probing into the role of HATs in gene regulation and cell cycle and may be useful as new chemical entities for the development of new drugs.
ISSN:0006-2952
1873-2968
DOI:10.1016/j.bcp.2004.05.038